Atabak Mokari's Insider Trades & SAST Disclosures
Atabak Mokari's most recent trade in Corcept Therapeutics Inc was a trade of 140,000 Stock option (right to buy) done . Disclosure was reported to the exchange on Feb. 28, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Atabak Mokari.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 140,000 | 140,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 232 | 13,034 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 59.07 per share. | 28 Feb 2025 | 232 | 12,802 (0%) | 0% | 59.1 | 13,704 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.58 per share. | 28 Feb 2025 | 228 | 12,570 (0%) | 0% | 60.6 | 13,812 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2024 | 231 | 12,798 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 59.21 per share. | 02 Dec 2024 | 231 | 12,567 (0%) | 0% | 59.2 | 13,678 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 57.68 per share. | 02 Dec 2024 | 182 | 12,336 (0%) | 0% | 57.7 | 10,498 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 400 | 12,518 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 34.26 per share. | 03 Sep 2024 | 400 | 12,118 (0%) | 0% | 34.3 | 13,704 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.30 per share. | 03 Sep 2024 | 143 | 11,718 (0%) | 0% | 35.3 | 5,048 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 1,448 | 11,861 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 31.30 per share. | 03 Jun 2024 | 1,448 | 10,413 (0%) | 0% | 31.3 | 45,322 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.17 per share. | 03 Jun 2024 | 571 | 8,965 (0%) | 0% | 30.2 | 17,227 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 24.06 per share. | 01 Mar 2024 | 554 | 8,982 (0%) | 0% | 24.1 | 13,329 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 554 | 9,536 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.06 per share. | 01 Mar 2024 | 517 | 8,428 (0%) | 0% | 24.1 | 12,439 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 200,000 | 200,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 508 | 8,945 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 25.97 per share. | 01 Dec 2023 | 508 | 8,437 (0%) | 0% | 26.0 | 13,193 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 1,651 | 7,408 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 22.97 per share. | 01 Jun 2023 | 1,651 | 5,757 (0%) | 0% | 23.0 | 37,923 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 19.86 per share. | 01 Mar 2023 | 1,260 | 2,846 (0%) | 0% | 19.9 | 25,024 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 1,260 | 4,106 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 793 | 1,586 (0%) | 0% | 0 | Common Stock | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 25.98 per share. | 01 Sep 2022 | 793 | 793 (0%) | 0% | 26.0 | 20,602 | Common Stock |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2022 | 200,000 | 200,000 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges